Skip to main content

Table 3 Additional treatment in CXCL13- high and CXCL13- low group

From: CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

 

DMARD + ADA

DMARD

 

CXCL13-high

CXCL13-low

CXCL13-high

CXCL13-low

Additional treatment

6/27, 22.2%

4/10, 40%

9/23, 39,1%

6/16, 37,5%

  1. Number of patients in the CXCL13-high and -low group treated with additional DMARDs than MTX. If sulphasalazine, hydroxychloroquine or both has been added to the treatment during the 2-year follow-up patients will be considered to be receiving additional treatment. x/y represents the number of patients receiving additional treatment/number of patients in the group. ADA: adalimumab; CXCR13: C-X-C chemokine receptor type 13; DMARD: disease-modifying anti-rheumatic drug.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us